Cost-effectiveness of pazopanib compared with sunitinib in metastatic renal cell carcinoma in Canada.

Amdahl, J; Diaz, J; Park, J; Nakhaipour, H R; Delea, T E

Amdahl, J; Diaz, J; Park, J; Nakhaipour, H R; Delea, T E.

Afiliación

Amdahl J; Policy Analysis Inc. ( pai ), Brookline, MA, U.S.A.;
Diaz J; Bristol-Myers Squibb, Twickenham, Greater London, U.K.;
Park J; Novartis Pharmaceuticals Corporation, East Hanover, NJ, U.S.A.;
Nakhaipour HR; GlaxoSmith-Kline, Health Outcomes-Oncology, Mississauga, ON.
Delea TE; Policy Analysis Inc. ( pai ), Brookline, MA, U.S.A.;

Curr Oncol ; 23(4): e340-54, 2016 Aug.

Article en En | MEDLINE | ID: mdl-27536183

Palabras clave

Cost-effectiveness analyses; economic evaluations; partitioned-survival analyses; pazopanib; post-progression survival analyses; quality-adjusted life-years; sensitivity analyses; sunitinib

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Health_economic_evaluation / Prognostic_studies Aspecto: Patient_preference Idioma: En Revista: Curr Oncol Año: 2016 Tipo del documento: Article Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google